Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

BACKGROUND: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment with curative intent holds promise to identify patients at risk of relapse. New methods can detect circulating tumour DNA (ctDNA) in plasma to fractional concentrations as...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Gale, D., Heider, K., Ruiz-Valdepenas, A., Hackinger, S., Perry, M., Marsico, G., Rundell, V., Wulff, J., Sharma, G., Knock, H., Castedo, J., Cooper, W., Zhao, H., Smith, C.G., Garg, S., Anand, S., Howarth, K., Gilligan, D., Harden, S.V., Rassl, D.M., Rintoul, R.C., Rosenfeld, N.
Formatua: Online Artikulua Texto
Hizkuntza:English
Argitaratua: Oxford University Press 2022
Gaiak:
Original Article
Sarrera elektronikoa:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067454/
https://www.ncbi.nlm.nih.gov/pubmed/35306155
http://dx.doi.org/10.1016/j.annonc.2022.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067454/
https://www.ncbi.nlm.nih.gov/pubmed/35306155
http://dx.doi.org/10.1016/j.annonc.2022.02.007

Antzeko izenburuak